此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

黑麻利2型反应患者的疗效和安全研究

2026年11月1日 更新者:Medicines Development for Global Health

一项为期12周的开放标签,随机,护理标准控制的,剂量的安全性和功效研究,对中度至重度急性或复发性麻风病患者的多vramilast研究

Dovramilast has not been approved for leprosy type 2 reaction (erythema nodosum leprosum, ENL) or any other disease anywhere in the world. In this study, an experimental drug called dovramilast is being tested to see how it compares to current treatments for leprosy type 2 reaction. Specifically, this study aims to assess the efficacy of 100mg or 150 mg dovramilast compared with standard treatments (also known as standard of care). This study also aims to assess the safety of two strengths in adults with leprosy type 2 reaction.

研究概览

研究类型

介入性

注册 (估计的)

45

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Yogyakarta、印度尼西亚
        • 招聘中
        • Universitas Gadjah Mada
        • 接触:
      • Divo、科特迪瓦
        • 尚未招聘
        • Chr de Divo
    • Washington
      • Seattle、Washington、美国、98104
        • 招聘中
        • Harborview Medical Center, University of Washington
        • 接触:
          • Dr Jason Simmons, MD, PhD
          • 电话号码:206-744-5463
          • 邮箱:jasonds@uw.edu
      • Manila、菲律宾
        • 招聘中
        • Philippine General Hospital, University of the Philippines, Manila
        • 接触:
      • Abomey-Calavi、贝宁
        • 尚未招聘
        • Centre de Dépistage de Traitement de la Lèpre et de l'Ulcère de Burulli
      • Tôlanaro、马达加斯加
        • 招聘中
        • Programme national lutte contre la lèpre
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Aged 18 years of age or older.

  2. Provision of written informed consent.

  3. Laboratory confirmed previous or current Mycobacterium leprae or Mycobacterium lepromatosis infection.

  4. Leprosy type 2 reaction meeting the following criteria:

    • Either:

      i. Acute (first episode and no treatment initiated) or ii. Recurrent (at least one further episode occurring 28 days or more after withdrawal of leprosy type 2 reaction treatment).

    • Presence of at least 10 leprosy type 2 reaction tender papular and/or nodular skin lesions (not including scars).

    • An ENLIST score of at least 9.

  5. If a woman of reproductive potential, agree to the use of two reliable contraceptive measures (at least one of which is a highly effective form of contraception) from Screening until at least 4 weeks after completion of treatment with dovramilast or standard of care. Refer to Special Considerations for additional information.

  6. If male (including those who have had a successful vasectomy), agree to using a latex condom during any sexual contact with women of reproductive potential from Screening until at least 4 weeks after completion of treatment with dovramilast or standard of care.

Exclusion Criteria:

  1. Chronic leprosy type 2 reaction, defined as the reaction occurring for 24 weeks or more during which a subject has required treatment either continuously or where any treatment free period had been < 28 days.

  2. Receipt of thalidomide, lenalidomide, pomalidomide, systemic corticosteroids, clofazimine (> 50 mg/day), apremilast or any other phosphodiesterase (PDE) 4 inhibitor, or immunosuppressive/immunomodulatory treatment within 28 days of Baseline.

  3. Receipt of an investigational agent within 28 days of Baseline or 5 half-lives of the investigational agent (whichever is longer).

  4. Leprosy type 2 reaction with orchitis, uveitis, iritis, or severe neuritis (Grade 3 or greater severe neuritis).

  5. Current diagnosis of leprosy type 1 reaction or Lucio's phenomenon.

  6. Current tuberculosis, malaria, cutaneous or visceral leishmaniasis or other serious bacterial, viral, or parasitic infection at Screening or Baseline.

  7. Active systemic fungal infection requiring or undergoing treatment.

  8. Other than leprosy type 2 reaction, any clinically significant (as determined by the Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is currently uncontrolled.

  9. Other than leprosy type 2 reaction, any other dermatological condition that could, in the opinion of the Investigator, interfere with the study assessments.

  10. Chronic hepatitis B, chronic hepatitis C, or human immunodeficiency virus (HIV) positive.

  11. Pregnant women or breastfeeding mothers.

  12. Use (or planned use) of antimetabolites or alkylating agents, rifampin use more frequent than monthly, phenobarbital, carbamazepine, phenytoin, traditional or herbal preparations (including St. John's wort), foods (including grapefruit) known to affect activity of the cytochrome (CYP)3A4 enzyme; of all strong CYP3A and P-gp inhibitors including ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, ritonavir, cobicistat, diltiazem; and sensitive substrates of CYP3A4, CYP2C9, CYP2C19, and P-gp. Other CYP3A4, CYP2C9, CYP2C19, and P-gp non-sensitive substrates should be used with caution when concomitantly administered with dovramilast.

  13. Known or suspected active substance abuse or a history of substance abuse within 6 months prior to Screening.

  14. Prior history of suicide attempt at any time in the subject's lifetime prior to Screening or Randomization, or major psychiatric illness requiring hospitalization within the last 3 years.

  15. Current diagnosis of depression, and/or history of suicide ideation

  16. History of or presence of cardiac disease, including:

    • Clinically significant abnormal electrocardiogram
    • QTcF > 450 msec
  17. Receipt of a vaccination within 7 days of Baseline.

  18. Known or suspected hypersensitivity to: PDE4 inhibitors including dovramilast or apremilast; thalidomide; prednisolone, or; excipients used in the formulation of dovramilast, thalidomide or prednisolone.

  19. Body Mass Index < 15 kg/m^2 or > 35 kg/m^2.

  20. Unable to, or significant difficulty with, swallowing tablets/capsules.

  21. Anemia requiring transfusion.

  22. History of or current pancreatitis.

  23. Known or suspected cirrhosis of the liver.

  24. The following laboratory abnormalities:

    • White blood cells (WBC) < 2.5 x 10^9/ L.
    • Neutrophils (granulocytes) < 1.0 x 10^9/L.
    • Platelets < 80 x 10^9/L.
    • Aspartate aminotransferase or alanine aminotransferase > 2 times the upper limit of reference range.
    • Albumin < 30 mg/dL.
    • Bilirubin > 2 mg/dL
    • Calculated creatinine clearance (Cockcroft Gault) < 50 milliliter (mL)/minute.
    • Lipase ≥ 1.6 times the upper limit
  25. Previous participation in this study

  26. Unwilling, unlikely or unable to comply with all protocol specified assessments, including photographic assessments

  27. Enrolled in another leprosy type 2 reaction treatment study

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:多vramilast 100毫克

Dovramilast

实验性的:多vramilast 150毫克

Dovramilast

有源比较器:Standard of care

Prednisolone (or thalidomide US sites only)

Standard of care

Standard of care (US only)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
The proportion of dovramilast (100 mg or 150 mg) recipients achieving a 75% improvement in leprosy type 2 reaction skin lesions at week 12
大体时间:12 weeks

The proportion of subjects achieving a reduction of leprosy type 2 reaction skin lesion count of at least 75% from Baseline at Week 12 without the need for rescue.

Rescue is defined as:

  1. A change from dovramilast at any dose to standard of care or dose maintenance beyond taper time points defined in standard of care treatment guidelines (and specified in this protocol), or
  2. Standard of care dose increase, switching to or adding another leprosy type 2 reaction treatment
12 weeks
Incidence and severity of adverse events
大体时间:12 weeks

The incidence and severity of adverse events, changes in vital signs and blood dyscrasias

12 weeks

次要结果测量

结果测量
措施说明
大体时间
从基线入伍(红斑麻风病)的变化严重程度量表评分
大体时间:在每个基准时间点
在每个基准时间点
基线等级的神经病的变化
大体时间:12周
12周
需要救援药物的受试者的比例和启动救援药物的时间
大体时间:12周
12周
施用的麻风病的总治疗总量
大体时间:12周
12周
Resolution of fever to ≤ Grade 1
大体时间:12 weeks

Proportion of subjects with resolution of fever to ≤ Grade 1 among the subgroup of subjects with fever present at Baseline at Grade 2 or greater.

12 weeks
Skin lesion count changes
大体时间:12 weeks

• Change from Baseline in skin lesion count up to and including Week 12.

12 weeks
Change from Baseline of each of the following parameters when present at Baseline at Grade 2 or greater
大体时间:from baseline to Week 12
  • Leprosy type 2 reaction lesions with respect to: number, inflammation, and extent
  • Neuritis
  • Pain:
  • Fever
  • Peripheral edema with respect to location and severity
  • Inflammation of joints and/or digits
  • Lymphadenopathy
from baseline to Week 12
Time to resolution
大体时间:12 weeks

For each individual leprosy type 2 reaction when present at least Grade 1 at Baseline

12 weeks
Recurrences
大体时间:48 weeks

Recurrence is defined as new signs and symptoms consistent with leprosy type 2 reaction. The number of Recurrence episodes requiring treatment.

48 weeks
Exposure metrics of dovramilast
大体时间:48 weeks

Area under the curve (AUC)

48 weeks
Exposure metrics of the dovramilast metabolite M15
大体时间:48 weeks

Area under the curve (AUC)

48 weeks
Skin lesion count changes
大体时间:12 weeks

• Proportion of Responders at each post-Baseline timepoint.

12 weeks
Skin lesion count changes
大体时间:12 weeks

Proportion of subjects achieving a reduction of leprosy type 2 reaction skin lesion count from Baseline of 50%, 90% and 100% without Rescue at Week 12.

12 weeks
Exposure metrics of dovramilast
大体时间:48 weeks

Including AUC, Cmax, and Tmax.

48 weeks
Exposure metrics of dovramilast
大体时间:48 weeks

Cmax

48 weeks
Exposure metrics of dovramilast
大体时间:48 weeks

Tmax.

48 weeks

其他结果措施

结果测量
措施说明
大体时间
Quantification of immunological markers in whole blood samples by central laboratory, blinded to patient identification, treatment arm, and study visit
大体时间:48 weeks

Concentration of inflammatory cytokines

48 weeks
Quantification of immunological markers in skin biopsies by central laboratory, blinded to patient identification, treatment arm, and study visit
大体时间:48 weeks

Leukocyte infiltration of skin lesions by histology

48 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年10月12日

初级完成 (估计的)

2027年1月1日

研究完成 (估计的)

2028年7月1日

研究注册日期

首次提交

2025年8月7日

首先提交符合 QC 标准的

2025年9月7日

首次发布 (实际的)

2025年9月15日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年11月1日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅